C1S

Complement C1s subcomponent · P09871 · C1S on Sugi Atlas →

8,488 patent compounds predicted against C1S, 5,860 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2599380	0.46	14/20
SCHEMBL2810572	0.68	13/20
SCHEMBL2624081	0.45	5/20
SCHEMBL600018	0.42	5/20
SCHEMBL1206446	0.52	4/20
SCHEMBL2056363	0.38	4/20
Hydrochloric Acid (SCHEMBL1436160)	0.58	3/20
Hydrochloric Acid (SCHEMBL2869263)	0.52	3/20
Hydrochloric Acid (SCHEMBL629198)	0.48	3/20
Trifluoroacetic Acid (SCHEMBL1950066)	0.43	3/20
Trifluoroacetic Acid (SCHEMBL1947449)	0.42	3/20
SCHEMBL1349683	0.41	3/20
SCHEMBL1349684	0.41	3/20
SCHEMBL755438	0.41	3/20
SCHEMBL423581	1.00	2/20
Benzamidine (SCHEMBL596593)	1.00	2/20
Benzamidine (SCHEMBL61379)	0.94	2/20
Benzamidine (SCHEMBL2877747)	0.84	2/20
Benzamidine (SCHEMBL650254)	0.80	2/20
Benzamidine (SCHEMBL871715)	0.80	2/20

Clinical trials — most relevant to C1S by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study to Evaluate the Benefit of RUCONEST® in Subjects Who Experience ADRs Related to IVIG Infusions	PHASE4	COMPLETED
Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE	PHASE4	COMPLETED
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema	PHASE2/PHASE3	COMPLETED
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema	PHASE3	COMPLETED
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN	PHASE3	RECRUITING
C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks	PHASE3	COMPLETED
Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks	PHASE3	COMPLETED
In Vivo Effects of C1-esterase Inhibitor on the Innate Immune Response During Human Endotoxemia - VECTOR II	PHASE3	COMPLETED
Donidalorsen Treatment in Children With Hereditary Angioedema	PHASE3	RECRUITING
C1 Esterase Inhibitor (C1INH-nf) for the Prevention of Acute Hereditary Angioedema (HAE) Attacks	PHASE3	COMPLETED
A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema	PHASE3	COMPLETED
Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis	PHASE2	COMPLETED
Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection	PHASE1/PHASE2	COMPLETED
Kinetics, Efficacy and Safety of C1-Esteraseremmer-N	PHASE2	COMPLETED
C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation	PHASE1	COMPLETED
TP10 Use in Patients With C3 Glomerulopathy (C3G)	PHASE1	WITHDRAWN
To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects	PHASE1	COMPLETED
Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy	PHASE1	COMPLETED
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia	PHASE1	WITHDRAWN
Study To Evaluate the Safety, Tolerability, and Pharmacokinetics After Subcutaneous Administration of C1K in Healthy Subjects	PHASE1	COMPLETED
Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)	nan	RECRUITING
Nafamostat Mesilate for Anticoagulation During CRRT in Critically Ill Patients	nan	UNKNOWN
Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome	nan	COMPLETED
Complement Activation in the Lysosomal Storage Disorders	nan	WITHDRAWN
Complement C5a Receptors in Hidradenitis Suppurativa	nan	COMPLETED
Effect of Platelet Storage on Complement Activation	nan	UNKNOWN
Complement and Graft-versus-host Disease	nan	COMPLETED
Transcriptome and Metabolic Analyses of CHAPLE Disease	nan	UNKNOWN
Significance of Ficolin 2 in the Determination of Serological Activity in Chronic Inflammatory Bowel Disease	nan	COMPLETED
DKK-3 rs11544814 and CFH rs10737680 Polymorphism and Protein Levels With Non Surgical Periodontal Therapy in Periodontitis Patients With and Without CAD	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a C1S binder may also engage these)

Protein	Name	Similarity
Q8CFG8	—	1.000	Q8CFG8 →
Q69DK8	—	1.000	Q69DK8 →
Q0VCX1	—	0.999	Q0VCX1 →
Q6P6T1	—	0.997	Q6P6T1 →
P15156	—	0.996	P15156 →
Q8CG14	—	0.995	Q8CG14 →
Q5R544	—	0.994	Q5R544 →
Q4R577	—	0.993	Q4R577 →
Q5R1W3	—	0.993	Q5R1W3 →
Q8CG16	—	0.992	Q8CG16 →
Q8CFG9	—	0.987	Q8CFG9 →
C1R	Complement C1r subcomponent	0.987	landscape →
Q62381	—	0.985	Q62381 →
Q91WP0	—	0.983	Q91WP0 →
P98063	—	0.983	P98063 →
O57460	—	0.982	O57460 →
Q20176	—	0.982	Q20176 →
O88947	—	0.981	O88947 →
ST14	Suppressor of tumorigenicity 14 protein	0.981	landscape →
P56677	—	0.981	P56677 →
Q9WVM6	—	0.981	Q9WVM6 →
TLL2	Tolloid-like protein 2	0.980	landscape →
Q8QFX6	—	0.980	Q8QFX6 →
P49150	—	0.980	P49150 →
P18292	—	0.980	P18292 →
TLL1	Tolloid-like protein 1	0.979	landscape →
O57382	—	0.979	O57382 →
BMP1	Bone morphogenetic protein 1	0.979	landscape →
P81187	—	0.978	P81187 →
Q5E9Z2	—	0.978	Q5E9Z2 →